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embryonic stem cells (hESCs) have the potential to overcome WNT/b-catenin pathway results in improved differentiation of
the shortage of primary hepatocytes for clinical use and drug
development. Many strategies for this process have been
reported, but the functionality of the resulting cells is incomplete.
We hypothesize that the functionality of hPSC-derived hepato-
cytes might be improved by making the differentiation method
more similar to normal in vivo hepatic development.
Methods:We tested combinations of growth factors and small
molecules targeting candidate signaling pathways culled from
the literature to identify optimal conditions for differentiation
of hESCs to hepatocytes, using qRT-PCR for stage-specific markers
to identify the best conditions. Immunocytochemistry was then
used to validate the selected conditions. Finally, induction of
expression of metabolic enzymes in terminally differentiated
cells was used to assess the functionality of the hESC-derived
hepatocytes.
Results: Optimal differentiation of hESCs was attained using a 5-
stage protocol. After initial induction of definitive endoderm
(stage 1), we showed that inhibition of the WNT/b-catenin path-
way during the 2nd and 3rd stages of differentiation was required
to specify first posterior foregut, and then hepatic gut cells. In
contrast, during the 4th stage of differentiation, we found that
activation of the WNT/b-catenin pathway allowed generation of
proliferative bipotent hepatoblasts, which then were efficiently
differentiated into hepatocytes in the 5th stage by dual inhibition
of TGF-b and NOTCH signaling.Journal of Hepatology 20
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End-stage liver disease is a major health problem affecting over
600 million people world-wide and 30 million within the US
and for many of these patients, liver transplantation is the only
effective long-term treatment. Given that the supply of cadaveric
livers for transplantation is limited, the use of primary fetal or
cadaveric hepatocytes directly transplanted or integrated to a
bioartificial device has been proposed as an alternative to whole
organ transplantation [1,2]. However, it is widely appreciated
that it is difficult to culture and amplify primary hepatocytes
while preserving their function [3]. Therefore, there is a need
for alternative sources of large numbers of functional hepato-
cytes. Human pluripotent stem cells (hPSC) have the ability to
self-renew and proliferate indefinitely in vitro and to differentiate
into a wide range of cell types, including hepatocytes [4–7], and it
has been widely appreciated that such cells might be useful for
clinical applications [8–10].
Although a number of methods for direct conversion of one
differentiated cell type to another have been described [11], the
majority of successful strategies for generating large numbers
of differentiated cells attempt to recapitulate the normal devel-
opmental progression from the pluripotent to the terminally dif-
ferentiated state [6,4,12]. In these strategies, pluripotent cells are
progressively directed by external signals, first to one of the three
germ lineages, and then to more specific downstream cell types.
The liver is derived from the endoderm lineage, which also gives
rise to the lung, pancreas, and gastrointestinal tract (GI).
Tracing the progression of specification from definitive
endoderm (DE) to hepatocyte, the endoderm first gives rise to
the primitive gut tube, which is patterned along the anterior-
posterior axis as it receives signals from the adjacent mesoderm.
Next, the posterior region of the gut is exposed to fibroblast
growth factor 4 (FGF4) [13] and wingless-type MMTV integration
site family (WNT), again from the mesoderm, and begins
to express CDX2, which leads to the formation of the16 vol. 64 j 1315–1326
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gastrointestinal tract. Concurrent repression of WNT signaling
ventral to this region of development of the GI tract results in
specification of the posterior foregut (PFG) expressing hepatocyte
nuclear factor 1-beta (HNF1b), HNF4, and hematopoietically-
expressed homeobox protein (HHEX), from which the liver and
pancreas are derived [14]. In fact, activation and inhibition of
the WNT pathway have been used to direct differentiation of
hPSCs into intestinal cells [15] and foregut derivatives [16,17],
respectively.
Subsequently, at a timepoint corresponding day 8.5 of mouse
embryonic development, the hepatic and pancreatic sublineages
(characterized by expression of alpha-fetoprotein (AFP) and pan-
creatic and duodenal homeobox 1 (PDX1), respectively) diverge
from a common ventral PFG domain [18]. This process is directed
by transforming growth factor beta (TGF-b), bone morphogenetic
protein 4 (BMP4), FGF4 and sonic hedgehog (SHH), which are
secreted from the surrounding mesoderm [19,18], with FGF4 at
this stage being primarily associated with liver development,
pancreatic development being characterized by inhibition of
BMP4 and SHH signaling, and TGF-b playing a more complex role
in both sublineages.
Shortly after the hepatic specification, hepatoblasts delami-
nate from the diverticulum and migrate through the septum
transversum (STM) to form the liver bud. Up until E13.5 in
mouse development, TBX3 maintains proliferative hepatoblasts
in a bipotent state, capable of becoming both hepatocytes and
cholangiocytes [20]. From E13.5, the hepatoblasts that are in
contact with the portal vein receive signals from the vascular
endothelial cells through direct cell-cell contact, which active
the NOTCH pathway, resulting in expression of SOX9 [21]. To
our knowledge, this signaling pathway has not been employed
in hPSC-to-hepatocyte differentiation strategies but has been
employed to differentiate human and mouse bipotent progeni-
tors into hepatocytes [22,23] and direct reprogramming of
fibroblast to hepatocyte [24]. Instead, the majority of hepatic
differentiation protocols established thus far have used a com-
bination of hepatocyte growth factor (HGF) and oncostatin M
(OSM) to drive hepatic progenitors towards a more hepatocyte
state [25,5,4,7]. Using this approach, generation of metaboli-
cally functional hepatocytes has been achieved, but only expos-
ing the cells to undefined conditions (e.g. fetal bovine serum,
matrigel, etc.) for extended periods of time [5,7]. Another iso-
lated study has reported the use of cell dissociation during
the differentiation process to promote hepatocyte maturation
[26].
Here, we report a new approach to differentiating human
embryonic stem cells (hESCs) into functional hepatocytes by
refining the steps of our previously described protocol by more
closely reproducing the steps involved in normal hepatic devel-
opment [6]. This new differentiation protocol drives differenti-
ation of hESCs into hepatocytes through 5 stages. During this
differentiation process, the cells faithfully express the key tran-
scription factors characteristic to each stage of liver organogen-
esis. We observe the generation of a proliferative hepatoblast
population that expresses both hepatic and cholangiocyte
markers, as well as PROX1 and HNF6, which have been shown
to be associated with successful generation of functional hepa-
tocytes in a previous report [26]. Key to our strategy, we use
inhibition of the NOTCH and TGF-b pathway to direct hepato-
cyte differentiation from hepatoblasts. The hepatocytes we
have generated using this new method express high levels of1316 Journal of Hepatology 2016hepatocyte specific genes, including metabolic genes encoding
key metabolic enzymes, and also display the appropriate meta-
bolic activities.Materials and methods
Culture and differentiation of human pluripotent stem cells
hESCs (H9/WA09 from WiCell, Madison, WI, USA) were maintained as colonies in
mTeSR1 medium on growth factor-reduced matrigel (BD Bioscience) and pas-
saged every 5 days using Cell Dissociation Buffer (StemCell Technologies). hiPSCs
were generated by reprogramming human dermal fibroblast (HDF) cultures using
standard reprogramming factors carried by Sendai virus vectors (Cytotune Kit,
from Life Technologies). hiPSC1 was reprogrammed from HDFs from an individual
with type 2 Crigler-Najjar Syndrome (Coriell, GMO9551), and hiPSC2 from HDFs
from a healthy individual. For differentiation experiments, cells were passaged
onto gelatin/FBS coated plates as previously described [6], and differentiation
was initiated 48 h after passage. To optimize hepatic differentiation of hESCs,
we modified a protocol previous published in [6] by testing several different com-
binations of factors and small molecules at stages 2, 3, 4, and 5 of differentiation.
Details of the differentiation method and supplementary information are
described in the Supplementary material.
Isolation and culture of adult primary hepatocytes
In order to obtain the highest possible quality of adult primary hepatocytes, for
the freshly isolated human adult hepatocyte (FI-HAH) preparations, donor livers
were collected directly from the operating room, the whole liver was perfused
with dissociation buffer, and the analysis of the freshly isolated cells was com-
pleted within 6 days of isolation, as described in detail in the Supplementary
material.Results
We have reviewed recent discoveries in developmental biology
elucidating the signaling pathways involved in normal hepatic
development to refine our previously reported protocol for
directed differentiation of hESCs to hepatocytes. Our newmethod
consists of 5 stages of differentiation, compared to the previously
published 4-stage method, as shown in Fig. 1. Major alterations in
the procedure include inhibition of the WNT pathway to pattern
DE cells to ventral PFG, the generation of hepatoblasts through
activation of the WNT pathway, and finally dual inhibition of
TGF-b and NOTCH signaling to promote hepatocyte differentia-
tion from the hepatoblast stage.
Differentiation of hESCs into ventral posterior foregut cells
During the first stage of differentiation, the cells were differenti-
ated to a near homogenous population of DE using a previously
published method [6]. The DE cells expressed the typical DE
markers SOX17, FOXA2, GATA4, but not the pluripotency-
associated markers OCT4 and SOX2 (Fig. 2 and Supplementary
Figs. 1, 2). We then wished to optimize the commitment of these
DE cells into PFG.
We screened selected growth factors and inhibitors target-
ing the TGF-b, BMP4, and WNT signaling pathways to identify
the best combination for induction of PFG. Specifically, we used
the BMP4 antagonist noggin (NOG), which has been previously
used to generate anterior foregut (AFG) and PFG [16,27], the
TGF-b family member Activin A [12], and the WNT/b-catenin
inhibitor IWR-1 [17,16]. As expected, inhibition of BMP4vol. 64 j 1315–1326
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Fig. 1. Schematic representation of the differentiation protocols used to differentiate hESCs into fetal hepatocytes. (A) the method developed in the current study. (B)
the previously developed protocol per Touboul et al. LY: Ly 294002; SB: SB 431542; CHIR: CHIR99021; CE: Compound E; RA: Retinoic Acid.
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Fig. 2. Establishment of stage 2 differentiation conditions: Differentiation of DE to posterior foregut. (A) qRT-PCR analysis of gene expression of SOX17, SOX2, HHEX,
and HNF4 in undifferentiated hESCs, DE, and DE treated for 3 days in: media without additives (Ø) or in presence of increasing doses of Activin A, Noggin and/or IWR-1.
Gene expression levels were normalized to DE. (B) Immunocytochemistry showing expression of the PFG markers HNF4, SOX17, HNF1b after 3 days of treatment of DE cells
with IWR-1. (C) qRT-PCR analysis shows expression of HNF4 and HHEX in hESCs, DE cells were treated with IWR-1 or combination of IWR-1/NOG. Gene expression levels
were normalized to DE.
JOURNAL OF HEPATOLOGYsignaling by NOG induced expression of the AFG marker SOX2,
but failed to significantly induce expression of PFG genes HNF4
and HHEX (Fig. 2A). Activin A induced mild expression of HNF4;
but even at the highest dose, there was only no induction of
HHEX or SOX2 (Fig. 2A). IWR-1 significantly improved DE differ-
entiation to PFG, as demonstrated by the expression of the
markers HNF4, HHEX, and HNF1b (Fig. 2A–B), while maintain-
ing expression of SOX17 (Fig 2A–B). IWR-1 treated cells also
re-expressed SOX2, an AFG marker, but did not express theJournal of Hepatology 2016pluripotency transcription factor OCT4 (Supplementary Fig. 2).
Importantly, we noticed that in the absence of treatment, DE
cells spontaneously expressed gut marker HNF4, but not HHEX
(Fig. 2A). Moreover, we observed that the addition of BMP4
inhibition to inhibition of the WNT pathway in fact blocked
differentiation to PFG (Fig. 2C). Thus, our results showed that
inhibition of WNT/b-catenin during differentiation of hESC-
derived DE cells is sufficient to induce expression of key PFG
transcription factors.vol. 64 j 1315–1326 1317
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Differentiation of ventral posterior foregut cells into hepatic gut cells
We next addressed how to commit these PFG cells into our third
stage hepatic gut cells. At this stage of development, PFG cells
have the potential to give rise to the liver and pancreas. We
screened growth factors and small molecules targeting the
BMP4, TGF-b, and WNT pathways, as well as retinoic acid (RA),
which have been previously reported to commit PFG cells to
the hepatic lineage in vitro and in vivo [4,6,16].
We observed that exposure to either BMP4, SB431542 (SB), or
IWR-1 in the presence of RA resulted in induction of the hepatic
markers AFP and albumin (ALB), but not the other hepatic mark-
ers PROX1, CEBPA (Fig. 3A). Moreover, there was persistent
expression of the DE marker SOX17, as well as expression of the
hindgut marker CDX2, which are undesirable for this stage of
hepatic differentiation [18]. We then manipulated pairs of signal-
ing pathways (i.e. BMP4 + SB, BMP4 + IWR-1, and SB + IWR-1)
with and without RA, and demonstrated that in the absence of
RA, we saw higher induction of the hepatic markers AFP, ALB,
PROX1, and CEBPA, with low expression of SOX17 and CDX2. The
addition of RA to these pairs of factors resulted in reduced
expression of the four hepatic markers, and increased expression
of SOX17 and CDX2. Finally, the triple combination of BMP4, SB,
and IWR-1 results in the best overall induction of the four hepaticAFP/HNF6
A
B
GAAFP/HNF4AFP/HNF4
CEBPA SOX17
0
1
2
3
4
5
6
7
S
t 2BMP4                 SB
IWR-1
RA
+ + +
+ -
- + -
- + - +
- + + -+-
- + ++
++ - -
+ -+ +
-+
-
+ +
+ +
hE
SC
s
- + -
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
BMP4                 
SB
IWR-1
RA
+ + +
+ - -
- + +
-+
++ -
++ +
-+
-
+
- + -
R
el
at
iv
e 
ge
ne
ex
pr
es
si
on
AFP AL
0
5
10
15
20
25
30
35
40
45
50
BMP4                 
SB
IWR-1
RA
+ + +
+ - -
- + +
-+
++ -
++ +
-+
-
+
- + -
0
10
20
30
40
50
60
S
t 2BMP4                 SB
IWR-1
RA
+ + +
+ -
- + -
- + - +
- + + -+-
- + ++
++ - -
+ -+ +
-+
-
+ +
+ +
hE
SC
s
- + -
R
el
at
iv
e 
ge
ne
ex
pr
es
si
on
Fig. 3. Establishment of stage 3 differentiation conditions: Induction of hepatic gut fr
cells. PFG cells were exposed for 4 days to various combinations of BMP4, IWR-1, RA an
undifferentiated hESCs was quantified by qRT-PCR analysis and normalized to stage 2 IW
BMP4/SB/IWR-1 for 4 days was confirmed by immunocytochemistry.
1318 Journal of Hepatology 2016markers while reducing expression of the DE and gastrointestinal
markers. We showed in a specific comparison of IWR1/SB to
IWR1/SB/BMP4 that the inclusion of BMP4 increased the expres-
sion of HNF4 by 30% (Supplementary Fig. 3). We note that RA
appears not to promote specific differentiation to the hepatic lin-
eage, and instead leads to aberrant expression of the hindgut
marker CDX2 in hepatic cells, which is consistent with a findings
reported in a previous study on direct reprogramming methods
[28].
Using immunocytochemistry (ICC), we confirmed that cells
treated with the combination of BMP4, SB, and IWR-1 co-
expressed the hepatic gut marker AFP with both HNF4 and
HNF6. GATA4 was co-expressed with HNF4, consistent with an
early hepatic progenitor state. We also started to observe clusters
of PROX1/HNF6 positive cells (Fig. 3B), with more than 20% of the
cells being double positive for these two markers (Fig. 6A).
Generation of bipotent proliferative hepatoblasts
Once the liver domain has been established, the newly formed
liver bud, influenced by signals from the surrounding mes-
enchyme, enters a phase of growth during which hepatoblasts
proliferate and remain bipotent [20]. We investigated the
reported role of the WNT/b-catenin pathway in this processPROX1/HNF6TA4/AFP
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[29], which corresponds to our fourth stage of differentiation, as
well as soluble factors which are known to be involved during
in vivo hepatic growth, including HGF, TGF-b [30], and VEGF [31].
The strongest overall effect we saw was a strong induction of
TBX3, a member of the T-box gene family, by the GSK3 inhibitor,
CHIR 99021(CHIR), which activates the WNT/b-catenin pathway.
The addition of HGF, vascular endothelial growth factor (VEGF),
or TGF-b did not seem to appreciably modify the effect of CHIR.
During liver bud growth, TBX3 expression is maintained among
the proliferative hepatoblast population, and restricts early dif-
ferentiation towards hepatocytes [20]. In the conditions where
cells were treated with CHIR, expression of key transcription fac-
tors such as CEBPA (Fig. 4A and Supplementary Fig. 4) and HNF4
(data not shown) were maintained at the same level as in stage
3. In the absence of CHIR, cells appeared to differentiate towards
a more mature hepatocyte state, with reduced expression of the
hepatoblast and cholangiocyte markers TBX3 and CK19, and
increased expression of the later hepatic genes ALB and CK18.
Importantly, these cells exhibited features of bipotent hepato-
blasts, with co-expression of the early hepatocyte marker AFP
and the early cholangiocyte transcription factor SOX9 (Fig. 4B).
These cells were also shown to be proliferative by Ki67 staining,
with expression of AFP by both qRT-PCR and immunocytochem-
istry (Fig. 4A and B). This treatment is also, to our knowledge, the0.0
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Fig. 4. Establishment of stage 4 differentiation conditions: Generation of hepatoblast
for differentiation to hepatoblast. Hepatic gut cells were grown for 4 days in presence of
and cholangiocytes markers were analyzed by qRT-PCR and normalized to stage 3
immunocytochemistry after treatment with CHIR/TGF-b/HGF/VEGF for 4 days.
Journal of Hepatology 2016first to induce strong co-expression of the transcription factors
HNF6 and PROX1 (Fig. 4B), which have recently been shown to
be essential for proper maturation of hepatocytes derived from
hPSCs [26]. In this previous study, the authors reported that dis-
sociation of the cells during differentiation stimulated expression
of these two factors; in our protocol, we achieved induction using
the combination of CHIR, TGF-b, HGF, and VEGF without cell dis-
sociation. Our procedure uses physiological cues, rather than a
mechanical stimulus, which does not occur during normal liver
development, and also can introduce variability in the differenti-
ation process.
Differentiation of hepatoblasts into fetal hepatocytes
We then performed a final screening procedure to develop opti-
mal conditions for differentiation of the bipotent hepatoblasts
into fetal hepatocytes. The majority of the established protocols
for deriving hepatocytes from hPSCs use HGF and OSM, either
as a combination or in a sequential fashion [25,4,26]. HGF is com-
monly used in vitro in primary hepatocyte cultures and OSM has
been shown in vivo and in vitro to promote maturation of primary
hepatocytes, particularly in association with glucocorticoids [32].
The TGF-b and NOTCH signaling pathways have been shown to
direct the cell fate decision that directs hepatoblasts towards+
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the hepatocyte vs. the cholangiocyte lineage, with activation of
these pathways leading to the cholangiocyte lineage and inhibi-
tion favoring the hepatocyte lineage [33,34]. We decided to
investigate whether the use of TGF-b and NOTCH inhibitors
would promote differentiation of the hepatoblasts into fetal hep-
atocytes. Since HGF is ubiquitous in the culturing of primary hep-
atocytes, as well as hepatocytes derived from hPSCs, we
maintained the presence of HGF in our cultures at 25 ng/ml in
all of our conditions. When cells were cultured in the presence
of 25 ng/ml of HGF alone, expression of hepatic (alpha-1-
antitrypsin (AAT), AFP, and ALB) markers increased as expected.
However, CEBPA expression was decreased, indicating that there
may be insufficient signaling to allow for clear selection by the
hepatoblasts towards the downstream alternative fates (hepato-
cyte and cholangiocyte); we see further evidence of this with
the persistence of SOX9 (a cholangiocyte marker) expression
(Fig. 5A). The addition of SB resulting in improved expression of
CEBPA, while the inclusion of the inhibitor of NOTCH signaling,
Compound-E (CE, 0.5 lM), was associated with decreased expres-
sion of SOX9. OSM did not appear to influence the expression of
any of the tested markers. Therefore, we concluded that the opti-
mal culture condition for the hepatoblast to fetal hepatocyte
transition included HGF, SB, and CE. We then demonstrated that
this condition resulted in secretion of high levels of albumin
(48 lg/ml/day per million cells) (Fig. 5B).
Demonstration that the bipotent hepatoblast stage is dependent on
WNT signaling
To show that the induction of hepatoblast markers and the cell
proliferation were not simply due to time, and to further demon-
strate the role of WNT signaling in this process, we compared
HNF6, PROX1, and Ki67 expression in stage 3 cells (hepatic gut
cells) that were cultured for the same amount of time, but in
three different conditions: CHIR, TGF-b, HGF, and VEGF (our stageA
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combination with oncostatin m (OSM), CE, and SB. qRT-PCR analysis of hepatic (ALB, AFP,
were normalized to stage 4. (B) ELISA analysis showing secretion of albumin into the cult
1320 Journal of Hepatology 20164 condition); IWR-1, TGF-b, HGF, and VEGF (our stage 4 condi-
tion, but replacing WNT activation by CHIR with WNT inhibition
by IWR-1); and HGF, SB, and CE (our stage 5 condition, thus skip-
ping stage 4, similar to previously published methods) (Fig. 6A).
These results indicated that both the HNF6/PROX1 double posi-
tive population and the Ki67 positive population (indicating the
proliferative population) were significantly higher in our stage
4 cells, which was the condition that included WNT activation.
Importance of the hepatoblast stage on cell maturation
We next wanted to examine whether including a proliferative
hepatoblast stage (referred to as stage 4 in Fig. 1) would improve
the maturation of the cells at the final stage (stage 5 in Fig. 1) of
differentiation.
We exposed either stage 3 or stage 4 cells to the same matu-
ration (stage 5) conditions for 14 days. 24 h prior to collecting the
cells for analysis, we treated both cultures with TCDD, RIF, and
PB, which activate the nuclear receptors AhR, PXR, and CAR,
respectively. These receptors, once activated by their ligands,
induce the expression of metabolic enzymes and transporters
involved in the detoxification of both endogenous and xenobiotic
molecules, which is one of the major functions of the liver. After
treatment, we verified that these drugs did not negatively impact
cell differentiation by monitoring the expression of ALB and AFP.
We also noted that the level of AFP expression was significantly
lower in the cells that had passed through stage 4 (referred to
as ‘‘stage 3? 4? 5” cells), than in those that had been transi-
tioned directly from stage 3 to stage 5 (referred to as ‘‘stage
3? 5” cells) (Fig. 6B); in Supplementary Fig. 6, we show that
the level of expression of AFP in the 5-stage protocol peaked at
stage 4, and then decreased between stage 4 and stage 5, mimick-
ing the normal decrease in AFP expression with hepatic matura-
tion. By qRT-PCR, we observed that the stage 3? 4? 5 and
stage 3? 5 cells expressed similar levels of AhR transcript, andAFP
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Fig. 6. Importance of the hepatoblast stage for later cell maturation. (A) Effect of WNT/b-catenin activation on the generation of hepatoblasts. FACS analysis performed
on stage 3 cells and on stage 4 cells (stage 3 cells exposed for 4 days to: HGF/TGF-b/SB/CHIR; HGF/TGF-b/SB/IWR-1; HGF/CE/SB). Each column represents the average of 3
independent biological replicates. ⁄p <0.02; ⁄⁄p <0.03. (B) and (C) qRT-PCR analysis of hESCs-derived hepatocytes generated by culturing stage 3 (St3? St5) or stage 4
(St3? St4? St5) for 14 days in HGF/CE/SB. Also represented gene expressions of human fetal and adult hepatocytes respectively abbreviated HFH and HAH. Gene
expression was normalized to freshly isolated human adult hepatocytes (HAH) (B) Gene expression analysis of the common hepatic markers ALB and AFP in hESC-derived
hepatocytes. (C) Expression of the transcripts for the nuclear receptors AhR and CAR, CYP family members in hESC-derived fetal hepatocytes. ⁄p <103; ⁄⁄p <2  102;
⁄⁄⁄p <104; ⁄⁄⁄⁄p <102, ⁄⁄⁄⁄⁄p <108, ⁄⁄⁄⁄⁄⁄p <106. (D) Immunocytochemistry for hepatic markers in the hESC-derived hepatocytes generated using the 5-stage protocol.
JOURNAL OF HEPATOLOGYthe stage 3? 4? 5 cells expressed lower levels of CAR transcript
(Fig. 6C). The level of expression of the nuclear receptor PXR was
very low for both types of cells (data not shown). Although theJournal of Hepatology 2016expression of the transcripts for the nuclear receptors did not
point to an advantage for including a hepatoblast stage (stage
4) in our differentiation protocol, we did observe interestingvol. 64 j 1315–1326 1321
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differences in the induction of downstream targets of these
receptors in responds to their ligands. Expression of CYP3A7
and CYP3A4 were significantly induced in the stage 3? 4? 5
cells, but not the stage 3? 5 cells, and expression of CYP1A1
was induced by both TCDD and PB, also only in stage
3? 4? 5 cells (Fig. 6C).
We also performed ICC on the stage 3? 4? 5 cells to evalu-
ate the expression of typical hepatocyte markers. Consistent with
the qRT-PCR data Fig. 6B, we saw near homogenous expression of
AFP and ALB. The albumin expressing cells were also positive for
HNF6, HNF4 and negative for the cholangiocyte marker SOX9,
consistent with their commitment to a hepatic fate [26]. Co-
expression of the hepatic transcription factors HNF6, PROX1,
HNF1a as well as expression of the cell surface marker asialogly-
coprotein receptor (ASGR) and the tight junction protein ZO-1,
further support that the cells are moving towards a functional
hepatocyte state (Fig. 6D) [35,26,25]. Finally, expression of the
phase II enzyme UGT1A1 and the phase I enzyme CYP3A4 could
be detected in these cells by ICC following treatment with pheno-
barbital (PB) (Fig. 6D), but not without induction (data not
shown).
We placed these results in the context of primary human fetal
hepatocytes (HFHs) and freshly isolated HAHs. We note that the
expression of ALB, AFP, AhR, and CAR were in fact higher in the
hepatocytes-like cells (HLCs) than in the HFHs or HAHs. The HFHs
showed the highest drug-induced expression of CYP3A7, while
the HAHs displayed the highest drug-induced expression of
CYP3A4 and CYP1A1, consistent with the known developmental
time course of expression of these metabolic enzymes. Compared
to HLCs and HFHs, HAH cells displayed higher than the HLCs. The
intermediate expression of CYP3A7, CYP3A4, and CYP1A1 in the
HLCs, with levels between those seen in HFHs and HAHs, suggest
that HLCs are not fully mature, but have developed beyond the
stage present at 17 weeks gestation (the stage of development
at which the HFHs were isolated).
Thus, we have shown that including an intermediate prolif-
erative hepatoblast stage between the hepatic gut and fetal
hepatocyte stages results in the production of functional fetal
hepatocytes expressing the of the hepatic markers ALB, PROX1,
HNF6, AFP, and ASGR, as well as being receptive to induction of
the phase I and phase II enzymes CYP3A7, CYP3A4, CYP1A1,
and UGT1A1 (Supplementary Fig. 8) by the nuclear receptor
ligands TCDD and PB. We evaluated the expression of HNF4,
as well as the CYP3A7/CYP3A4 ratio, over the final stages of
differentiation, and compared them to HFHs and HAHs. As
expected, we found a decrease in HNF4 expression at stage 5
compare to stage 4. HNF4 expression at stage 5 remains higher
that in HFHs and HAHs (Supplementary Fig. 7A). CYP3A7/
CYP3A4 gene expression ratio shows show CYP3A7 expression
remains higher that CYP3A4 expression in HLC (Supplementary
Fig. 7B). Nevertheless, this ratio confirms the tendency
observed with the decrease of AFP expression, cells are under-
going towards a more mature state as this ratio is lower than
the ratio calculated for HFH.
To obtain a global view of the stage 5 cells differentiated using
our final protocol, in the context of normal human liver develop-
ment, we performed RNA sequencing of undifferentiated hESCs,
the stage 5 cells, and human fetal and adult liver. First, we iden-
tified transcripts that were differentially expressed between
undifferentiated hESCs, fetal liver, and adult liver, and then used
CLICK correlation clustering to place the stage 5 cells into this1322 Journal of Hepatology 2016context. The heat map and mean expression profile graphs
(Fig. 7) show that the stage 5 cells from the final differentiation
protocol are beginning to express typical hepatic transcripts
(Cluster 1), which include the transporters of the ABC family,
APO lipoprotein, CYP2E1 and 2C9 and other genes involved in
important hepatic functions (e.g. TAT, TDO2). As expected, the
results also indicate that the stage 5 cells are losing expression
of number of key pluripotency markers such as OCT4 and SOX2
(Cluster 2). Cluster 3 contains transcripts that are mostly highly
expressed in fetal liver, with essentially no expression in the
undifferentiated and adult liver samples, and low levels of
expression in the HLCs. Interestingly, Cluster 4 shows that the
stage 5 cells have begun to express markers specific of adult hep-
atocytes, which are not expressed in the fetal liver samples
(CYP2B6, CYP1A2, UGTs). Taken together, these genome-wide gene
expression results indicate that the HLCs are likely to be interme-
diate between the fetal and adult hepatocyte stages. This is con-
sistent with our qRT-PCR and ICC results shown above.
Finally, the function of the stage 5 cells was assessed using a
battery of phenotypic assays, including: CYP3A family, CYP1A1
and CYP2B6 activity with and without drug induction using
luminescence-based P450-Glo Assays (Promega) with the appro-
priate substrates (please see Materials and methods for details);
Periodic acid-Schiff (PAS) staining to demonstrate storage of
glycogen; Oil Red O (ORO) and BODIPY staining to evaluate lipid
storage; LDL uptake; and urea production. For the CYP assays, the
HLCs demonstrated statistically significant induction with the
appropriate drugs, at levels that were comparable to HFHs for
CYP1A1 (Fig. 8A and Supplementary Fig. 9). The urea production
was also comparable in the HLCs to HFHs (Fig. 8B). It is important
to note that freshly isolated adult hepatocytes showed higher
basal activity and induction of CYP2B6 and CYP1A1, as well as a
higher level of urea production (Fig. 8A and Supplementary
Fig. 9). Finally, positive staining for lipid, glycogen, and LDL in
the HLCs are shown in Fig. 8C.
To confirm the generalizability of our final hepatic differenti-
ation protocol to human induced pluripotent stem cells (hiPSCs),
we differentiated two hiPSC lines (hiPSC1, reprogrammed from
HDFs from an individual with type 2 Crigler-Najjar Syndrome;
and hiPSC2, reprogrammed from HDFs from a healthy individual),
and demonstrated excellent expression of the appropriate stage-
specific markers (Supplementary Fig. 10), as wells as inducible
CYP activity, urea production, and glycogen and lipid storage
(Supplementary Fig. 11).Discussion
In this study, we present a novel approach to generate fetal hep-
atocytes from hPSCs. Attempting to better recapitulate the events
in normal hepatic development in defined conditions, our new
method includes modulation of additional signaling pathways
that have not been addressed in previous protocols, and includes
an additional stage of differentiation, namely, proliferative hepa-
toblast. A number of previously published methods have reported
differentiation of hPSCs to metabolically functional hepatocytes,
but the resulting cells express markedly lower levels of mature
hepatocyte markers compared to adult hepatocytes [5,7]. It has
been suggested that one of the major deficiencies in existing
methods is that they do not include an intermediate stage of
differentiation in which the cells express critical transcriptionvol. 64 j 1315–1326
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JOURNAL OF HEPATOLOGYfactors necessary for later maturation of the cells, such as PROX1
and HNF6/ONECUT1 [26].
In order to correct these drawbacks, starting with DE gener-
ated using the defined method we reported in [6], we optimized
conditions for generating PFG cells, which are the common pro-
genitors for the hepatocytes and pancreatic lineages. Still using
defined factors, we have shown that inhibition of WNT/b-
catenin pathway by the chemical inhibitor IWR-1 was sufficient
to induce expression of a panel of genes, including HNF4, HNF1b,
and HHEX, which characterize the specification of PFG during
early development. Importantly, in contrast to a recent report
[16], we did not find it necessary to combineWNT inhibition with
retinoic acid and inhibition of FGF4 and BMP4 for efficient induc-
tion of PFG; on the contrary, we found that fibroblast growth fac-
tor (FGF) inhibition had a dramatic negative effect on HHEX
expression.Journal of Hepatology 2016We then improved conditions for establishing the hepatic gut
stage by combining findings from previous studies indicating that
stimulation of BMP4 [19,4,26] and inhibition of TGF-b [6,19,16]
are important for hepatic specification with knowledge gleaned
from developmental biology studies indicating that inhibition
of the WNT/b-catenin pathway is important for acquisition of
the hepatic and pancreatic domain across diverse species
[36,37,14]. Despite the fact that RA has frequently been used to
induce hepatic differentiation, our results indicated that it
strongly induced expression of the intestinal transcription factor
CDX2.
Postulating that incorporating a proliferative hepatoblast
stage would promote later maturation, we built upon the
observation that loss of WNT/b-catenin activity resulted in liver
hypoplasia at E12 of mouse embryogenesis and lethality at E17
[29], we used the GSK3 inhibitor CHIR99021 to activate thevol. 64 j 1315–1326 1323
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Research ArticleWNT/b-catenin pathway. We found that inclusion of CHIR
resulted in increased proliferation and induction of the transcrip-
tion factors TBX3, which has been shown to play a critical role
during liver bud formation by maintaining the pool of prolifera-
tive hepatoblasts by inhibiting their early differentiation into
hepatocytes [20], HNF6 and PROX1, which as we discussed above,
are associated with subsequent improved maturation.
In vitromaturation conditions typically include the use of HGF
and OSM. However, in vivo, bipotent hepatoblasts in contact with
the portal veins differentiated into cholangiocytes under TGF-b
and NOTCH signaling originating from the endothelial cells of
the portal veins [33,38]. In contrast, the cells that mature into
hepatocytes do not receive these signals. Here, we have shown
that dual inhibition of the NOTCH and TGF-b signaling pathways
in the presence of HGF are directed to a hepatocyte fate, with
rapid upregulation of ALB expression and maintenance of high
levels of expression of CEBPA and HNF1a, and downregulation
of the cholangiocyte-associated transcription factor SOX9. After
14 days in these maturation conditions, there was marked induc-
tion of several of the major hepatic enzymes via the nuclear
receptors CAR, AhR, and PXR. The expression of these enzymes
was responsive to induction by TCDD, Rifampicine and/or pheno-
barbital; this induction is a hallmark of functional hepatocytes
(fetal and adult).
Our results indicated that inclusion of the hepatoblast stage in
our differentiation protocol led to the strongest induction of
these enzymes with the appropriate drugs. Cells that were tran-
sitioned directly from the hepatic gut stage into maturations con-
ditions (without passing through the hepatoblast stage) at times
showed a higher basal level of expression some of the enzymes,
but did not show robust induction. The weak induction of PROX1
and HNF6 in the hepatic gut-to-maturation cells might be due to
exposure to the TGF-b inhibitor SB in the maturation conditions,
which may promote proliferation and maintenance of any hepa-
toblast cells that might be present, as was described in a study1324 Journal of Hepatology 2016that reported increased expansion of mouse hepatoblasts, not
only by CHIR, but also by a TGF-b inhibitor [22].
Considering our targeted and genome-wide gene expression,
immunocytochemistry, and functional results together, we con-
clude that our HLCs occupy a developmental stage intermediate
between fetal and adult hepatocytes. Although our cells are not
completely mature, they do express the hallmarks of fetal hepa-
tocytes in terms of expression of key metabolic enzymes and
detectable, but still low expression of the nuclear receptor PXR
[39,40]. Moreover, the inclusion of the hepatoblast stage was
associated with lower gene expression of AFP at the hepatocyte
stage, which is consistent with initiation of the transition from
fetal to adult hepatocytes (with decreased AFP expression and
increased ALB expression).
In summary, we have developed defined conditions for
directed differentiation of hESCs to hepatocytes using a 5 step
protocol that exposes the cells to a series of factors mimicking
the signals received during normal hepatic development, and
shown that the cells follow the progression of the differentiat-
ing cells through multiple progenitor stages from DE, through
the posterior foregut, hepatic gut, and hepatoblast stages, and
finally to fetal hepatocytes. This is the first report demonstrat-
ing that regulation of the WNT/b-catenin pathway should be
integrated not only for DE commitment, but also at the hepatic
gut and hepatoblast specification stages. Although our cells are
not fully mature and comparable freshly isolated adult hepato-
cytes, this work serves as a robust foundation for future studies
aimed at defining conditions for further maturation. For exam-
ple, although we found that inclusion of OSM for 4 days did
not appreciably improve maturation, it is possible that longer
periods of exposure to this factor may be beneficial. In addi-
tion, the ability to generate cells at a bipotent hepatoblast
stage will allow development of methods for directing differen-
tiation to the cholangiocyte fate, for which there are as yet few
reports [41].vol. 64 j 1315–1326
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